Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir

AIDS

Volumn 14, Issue 7, 2000, Pages 801-805

  Gisolf, Elisabeth H ^a,b   Van Heeswijk, Rolf P G ^a   Hoetelmans, Richard W M ^a   Danner, Sven A ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antiretroviral therapy; Pharmacokinetic profile; Ritonavir; Saquinavir

Indexed keywords

LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MALE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SAQUINAVIR; STAVUDINE; TIME FACTORS;

EID: 0034073929     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005050-00005     Document Type: Article

References (17)

1. 1. Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
2. 3 or less. N Engl J Med 1997, 337:725-733.
3. 3. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
4. 4. Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
5. 5. Wit FWNM, van Leeuwen R, Weverling GJ et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790-798.
6. 6. Enting RH, Hoetelmans RMW, Lange JMA, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998, 12:1941-1955.
7. 7. Khaliq Y, Gallicano K, Sahai J, Cameron DW et al. Effect of nelfinavir on short and long term plasma exposure of saquinavir in hard gel capsule during tid and bid dosing regimens. AIDS 1998, 12(suppl 4):S28.
8. 8. van Heeswijk RPG, Hoetelmans RMW, Harms R et al. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998, 719:159-168.
9. 9. ACTG criteria, Division of AIDS, Table for Grading Severity of Adult Adverse Experiences. August 1992.
10. 10. Hoetelmans RMW, Reijers MHE, Wit FWNM et al. Saquinavir pharmacokinetics in combination with nelfinavir in the ADAM study. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, October 1997 [abstract 255].
11. 11. Lee CGL, Gottesman MM, Cardarelli CO et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
12. 12. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multi-drug transporter P-glycoprotein in human cultured cells. J AIDS Res Hum Retroviruses 1998, 19:203-209.
13. 13. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999, 12:1623-1627.
14. 14. Hauser IA, Koziolek M, Hopfer U, Thevenod F. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998, 54:1139-1149.
15. 15. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112.
16. 16. Hoetelmans RMW, van Heeswijk RPG, Meenhorst PL, Mulder FW, Scheele WA, Beijnen FH. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period. XII International Conference on AIDS. Geneva, June 1998 [abstract 42261].
17. 17. Merry C, Barry MC, Mulcahy F, Halifax KL, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997, 11:F117-F120.